Beroni Group (?Beroni? or the ?Company?) announced that it has received part payment of a USD 1.07 million (JPY 117.5 million) order for its SARS-CoV-2 Antigen Test Kit from a Japanese pharmaceutical company based in Tokyo. Beroni has so far produced and delivered about two thirds of the test kits to the buyer. The SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) optimizes the sample collection process. It requires no blood, and only a nasopharyngeal swab is needed to collect samples. This greatly improves the convenience of testing and the test results can be obtained within 10 minutes. The antigen test kit was prepared using colloidal gold solid-phase immunochromatography and is used for qualitative assays of SARS-CoV-2 antigen samples in vitro. Based on the latest clinical study, it demonstrated an overall sensitivity of 95% and specificity of 100% and has received CE certification in December 2020. Recent COVID-19 cases and deaths have fallen dramatically throughout Japan as vaccinations have increased to cover more than 70% of the population. Japan has been using rapid antigen tests as one of the tools to contain outbreaks.